Hepatic vascular remodelling in a patient with dyskeratosis congenita

Telomere biology disorders (TBD), including dyskeratosis congenita (DC), are a group of accelerated aging diseases caused by mutations in genes encoding factors involved in telomere maintenance. Hepatic involvement affects 10-40% of TBD patients with nodular regenerative hyperplasia (NRH) and cirrhosis being the most common hepatic manifestations, both of which can result in portal hypertension (1-3). Lung involvement includes interstitial lung disease (ILD) such as idiopathic pulmonary fibrosis (IPF) and hepatopulmonary syndrome (HPS) which can be associated with portal hypertension. Vascular complications in TBD include pulmonary arteriovenous malformations, gastrointestinal telangiectasias and exudative vitreoretinopathy.

[1]  N. Young,et al.  The Spectrum of Hepatic Involvement in Patients With Telomere Disease , 2019, Hepatology.

[2]  Douglas A. Simonetto,et al.  Hepatic manifestations of telomere biology disorders. , 2018, Journal of hepatology.

[3]  M. Anglesio,et al.  Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage , 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  C. Gilks,et al.  High‐grade serous carcinoma of tubo‐ovarian origin: recent developments , 2017, Histopathology.

[5]  G. Raghu,et al.  Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders , 2017, European Respiratory Journal.

[6]  S. E. Stanley,et al.  Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. , 2015, Chest.

[7]  J. H. Price,et al.  Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype , 2010, Journal of Clinical Pathology.

[8]  S. Chanock,et al.  A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations , 2009, PloS one.

[9]  J. K. Dunn,et al.  Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. , 1997, American journal of clinical pathology.

[10]  V. Zurawski,et al.  Carcinoembryonic Antigen (CEA) and Carbohydrate Determinant 19–9 (CA 19–9) Localization in 121 Primary and Metastatic Ovarian Tumors: An Immunohistochemical Study with the Use of Monoclonal Antibodies , 1982, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.